Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
September 08, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed...
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
September 08, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and...
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
August 07, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
June 01, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry...
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 09, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
May 08, 2023 07:08 ET
|
Vigil Neuroscience, Inc.
– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease – – Through ALSPAware, individuals and healthcare...
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
March 30, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Stifel 2023 CNS Days
March 22, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...